MedTrace Logo

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

NCT04848272 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-04-17

No results posted yet for this study

Summary

Phase 1 study investigating safety of lanadelumab administration to patients with lung injury

Conditions

  • Lung Injury

Interventions

DRUG

Lanadelumab

Monoclonal antibody that targets active plasma kallikrein

OTHER

Saline control

Saline control

Sponsors & Collaborators

  • St Vincent's Institute of Medical Research

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04848272 on ClinicalTrials.gov